Today: 21 May 2026
Browse Category

BME:NTGY 11 December 2025 - 14 December 2025

IBEX 35 Week Ahead: Spain’s Bolsa de Madrid Outlook After Inditex Record, Naturgy Shock and ECB Countdown (Updated Dec 14, 2025)

IBEX 35 Week Ahead: Spain’s Bolsa de Madrid Outlook After Inditex Record, Naturgy Shock and ECB Countdown (Updated Dec 14, 2025)

Spain’s IBEX 35 closed last week at 16,854.4, up 0.99%, after briefly touching 17,000 points for the first time. Banks led gains, with the IBEX 35 Banks index up 1.39% weekly and 103.39% year-to-date, while energy stocks lagged. Naturgy dropped 8.53% after BlackRock sold a 7.1% stake for €1.7 billion. Markets await ECB signals and year-end flows.
14 December 2025
···
EU Stock Market Today, 11 December 2025: Cyclicals Rally While Tech Stumbles After Fed Rate Cut and SNB Hold

EU Stock Market Today, 11 December 2025: Cyclicals Rally While Tech Stumbles After Fed Rate Cut and SNB Hold

European stocks closed higher on December 11, with the STOXX Europe 600 up 0.66% and the Euro Stoxx 50 gaining 1.0%, as investors favored financials and cyclicals after the Fed’s rate cut. Germany’s DAX and Spain’s IBEX 35 hit new highs. Technology shares lagged, with SAP dropping up to 3% after Oracle’s weak outlook revived concerns over AI sector profits.
11 December 2025
····

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop